UK HealthTech Startup Raises Seed Funding for Supported Alcohol Reduction Programme
Nul, a pioneering UK-based HealthTech startup, has successfully raised nearly €840,000 ($1 million) in Seed funding to accelerate its supported alcohol reduction platform. The innovative telehealth service combines clinical care, prescription medication, and behavioural support to help individuals reduce their alcohol consumption through evidence-based treatment pathways.
The funding round was led by dmg ventures, the venture capital arm of Daily Mail and General Trust, alongside BYVP and a strategic group of angel investors with expertise spanning technology, healthcare, and consumer brands. This capital injection will fuel Nul’s UK commercial launch, team expansion, customer acquisition strategies, and preparation for international market entry, including the United States.
Addressing a Modernisation Gap in Healthcare
Matus Maar, founder and CEO of Nul, emphasized the significant opportunity in alcohol reduction treatment. “Alcohol reduction is one of the largest and least modernised areas in healthcare,” Maar explained. “Telehealth and online pharmacy platforms have transformed categories like weight loss and mental health, yet alcohol has been left behind despite the scale of the problem. Nul is about making evidence-based treatment accessible, discreet and compatible with real life.”
Founded by Maar, who previously co-founded Talis Capital, Nul represents a fresh approach to a persistent healthcare challenge. The platform addresses a critical market need where traditional in-person treatment options often create barriers to access, including stigma, scheduling conflicts, and geographic limitations.
The Science Behind Nul’s Approach
Nul’s core programme centers on naltrexone, an FDA-approved medication traditionally used to treat both opioid use disorder (OUD) and alcohol use disorder (AUD). Similar to GLP-1 medications, naltrexone works on reward pathways in the brain to reduce alcohol cravings and diminish the reinforcing effects of alcohol consumption.
The treatment protocol follows The Sinclair Method, an evidence-based approach that clinical studies have reported achieving success rates of up to 78% (Sinclair, John – Clinical Studies, 2001). This methodology combines medication with targeted behavioural interventions to support sustainable alcohol reduction.
Comprehensive Remote Care Delivery
Nul delivers its programme through a fully remote, subscription-based service that removes traditional barriers to treatment access. The platform includes virtual consultations with qualified healthcare professionals, ongoing clinical monitoring and support, and structured digital pathways designed to reinforce positive behavioural changes.
Strategic partnerships with established healthcare providers including Blueco Healthcare and Thriva enable Nul to maintain high clinical standards while ensuring seamless medication delivery and comprehensive patient care coordination.
Investor Confidence and Market Validation
Rachel Muzyczka, Partner at dmg ventures, expressed enthusiasm about Nul’s mission and market positioning. “Nul’s mission to empower individuals to take control of their relationship with alcohol is both timely and transformative,” Muzyczka stated. “Their approach is not only innovative but deeply aligned with the growing demand for healthier lifestyles. We see tremendous potential in their approach and the market they’re serving.”
Early Traction and Growth Metrics
Nul launched a UK test phase in summer 2025 and has already demonstrated strong market demand. The startup has onboarded more than 120 paying customers and reached an annualised revenue run-rate of nearly €344,000 (over £300,000) within its first few months of operation. This growth has been driven primarily through organic demand and word-of-mouth referrals, validating the platform’s value proposition and customer satisfaction.
Expansion Plans and Crowdfunding Initiative
In parallel with the Seed funding round, Nul plans to launch a crowdfunding campaign on Republic Europe later this week. This initiative will enable retail investors to participate in the company’s growth journey and support its expansion phase.
The company has outlined ambitious growth plans for 2026, including raising additional capital to scale operations across the UK market and enter new international territories. The dual funding approach—combining institutional investment with retail crowdfunding—demonstrates Nul’s commitment to building a community-supported healthcare solution.
With telehealth adoption accelerating and consumer demand for discreet, accessible healthcare solutions growing, Nul is positioned to transform how individuals access alcohol reduction support. The combination of clinical expertise, evidence-based medication protocols, and digital delivery infrastructure addresses a significant gap in modern healthcare services.
